Cargando…

Combination treatment of rituximab and donor platelets infusion to reduce donor‐specific anti‐HLA antibodies for stem cells engraftment in haploidentical transplantation

BACKGROUND: Donor‐specific anti‐human leukocyte antigen (HLA) antibodies (DSAs) in recipients is a risk factor for donor stem cell graft failure in haploidentical hematopoietic stem cell transplantation (haplo‐HSCT), and the treatment to reduce the levels of DSAs is not unanimous. This study was to...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhang, Rongli, He, Yi, Yang, Donglin, Jiang, Erlie, Ma, Qiaoling, Pang, Aiming, Zhai, Weihua, Wei, Jialin, Feng, Sizhou, Han, Mingzhe
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2020
Materias:	Research Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7370703/ https://www.ncbi.nlm.nih.gov/pubmed/32112480 http://dx.doi.org/10.1002/jcla.23261

Ejemplares similares

P1304: TREATMENT WITH COMBINATION OF RITUXIMAB AND INTRAVENOUS Γ GLOBULIN IS EFFECTIVE IN PROMOTING ENGRAFTMENT IN DONOR SPECIFIC ANTIBODY POSITIVE PATIENTS RECEIVING HAPLOIDENTICAL STEM CELL TRANSPLANT
por: Shen, Yuyan, et al.
Publicado: (2023)

Comparison of Hematopoietic Stem Cell Transplantation Outcomes Using Matched Sibling Donors, Haploidentical Donors, and Immunosuppressive Therapy for Patients With Acquired Aplastic Anemia
por: Zhang, Yuanfeng, et al.
Publicado: (2022)

Hematopoietic stem cell transplantation from an infected SARS-CoV2 haploidentical donor: A case report
por: Chen, Xin, et al.
Publicado: (2023)

Comparison of porcine ALG and rabbit ATG on outcomes of HLA-haploidentical hematopoietic stem cell transplantation for patients with acquired aplastic anemia
por: Chen, Juan, et al.
Publicado: (2022)

The prognostic impact of previously infectious complications on allogeneic hematopoietic stem cell transplantation for patients with severe aplastic anemia: A single-center, retrospective study
por: Zhang, Yuanfeng, et al.
Publicado: (2022)

Efficacy of Recombinant Human Thrombopoietin for the Treatment of Secondary Failure of Platelet Recovery After Allogeneic HSCT
por: Cao, Yigeng, et al.
Publicado: (2022)

Retrospective Comparison of Efficacy and Safety of Rabbit Anti-Thymocyte Globulin and Porcine Anti-Lymphocyte Globulin in Patients With Acquired Aplastic Anemia Undergoing Hematopoietic Stem Cell Transplantation From Matched Sibling Donors
por: Zhang, Yuanfeng, et al.
Publicado: (2022)

Cardiac involvement in a patient with B-cell lymphoblastic lymphoma/acute lymphoblastic leukemia and a history of allogeneic hematopoietic stem cell transplantation and CAR T-cell therapy: A case report
por: Cao, Yigeng, et al.
Publicado: (2023)

Intravenous-oral itraconazole versus oral posaconazole in preventing invasive fungal diseases for acute leukemia patients
por: Liu, Li, et al.
Publicado: (2023)

The outcome of acute leukemia patients with SET-NUP214 fusion after allogeneic stem cell transplantation
por: Shen, Yuyan, et al.
Publicado: (2023)

P1273: COMPARISON OF TOTAL BODY IRRADIATION-BASED WITH CHEMOTHERAPY-BASED MYELOABLATIVE CONDITIONING REGIMENS IN PATIENTS WITH B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA IN FIRST COMPLETE REMISSION
por: Mengnan, LV, et al.
Publicado: (2023)

PB1731: INOTUZUMAB OZOGAMICIN IN LYMPHOID B-CELL MALIGNANCY：A SINGLE CENTER ANALYSIS IN THE REAL WORLD
por: LV, Mengnan, et al.
Publicado: (2023)

Comparison of characteristics and outcomes on ETP-ALL/LBL and non-ETP ALL patients receiving allogeneic hematopoietic stem cell transplantation
por: Chen, Juan, et al.
Publicado: (2023)

P1262: GILTERITINIB MAINTENANCE AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR RELAPSED/REFRACTORY ACUTE MYELOID LEUKEMIA WITH FLT3–INTERNAL TANDEM DUPLICATION MUTATION
por: Liang, Chen, et al.
Publicado: (2023)

Outcome of autologous stem cell transplantation in patients with favorable-risk acute myeloid leukemia in first remission
por: Chen, Juan, et al.
Publicado: (2022)

Venetoclax plus hypomethylating agents versus intensive chemotherapy for hematological relapse of myeloid malignancies after allo-HSCT
por: Chen, Zhangjie, et al.
Publicado: (2023)

Risk factors for CMV infection within 100 days posttransplantation in patients with acute leukemia
por: Chen, Juan, et al.
Publicado: (2022)

Safety of in vitro amplified HLA-haploidentical donor immune cell infusions for childhood malignancies
por: Zhang, Fei, et al.
Publicado: (2013)

Clinical applications of donor lymphocyte infusion from an HLA-haploidentical donor: consensus recommendations from the Acute Leukemia Working Party of the EBMT
por: Dholaria, Bhagirathbhai, et al.
Publicado: (2020)

CD11c participates in triggering acute graft‐versus‐host disease during bone marrow transplantation
por: Wang, Qianqian, et al.
Publicado: (2021)

Haploidentical related donor compared to HLA-identical donor transplantation for chemosensitive Hodgkin lymphoma patients
por: Castagna, Luca, et al.
Publicado: (2020)

Risk factors associated with hemorrhagic cystitis after allogeneic hematopoietic stem cell transplantation
por: Shen, Biao, et al.
Publicado: (2022)

Long-term survivors demonstrate superior quality of life after haploidentical stem cell transplantation to matched sibling donor transplantation
por: Zhang, Xiaoyu, et al.
Publicado: (2022)

Co-infusion of high-dose haploidentical donor cells and CD19-targeted CART cells achieves complete remission, successful donor engraftment and significant CART amplification in advanced ALL
por: Yu, Changlin, et al.
Publicado: (2020)

Impact of Donor-Specific anti-HLA Antibodies and Donor KIR Characteristics in Haploidentical HSCT for Beta-Thalassemia
por: Andreani, Marco, et al.
Publicado: (2017)

Loss of Lkb1 impairs Treg function and stability to aggravate graft-versus-host disease after bone marrow transplantation
por: Su, Xiuhua, et al.
Publicado: (2019)

HLA-Haploidentical Family Donors: The New Promise for Childhood Acute Lymphoblastic Leukaemia?
por: Ab Rahman, Syaza, et al.
Publicado: (2022)

Case report: HLA-haploidentical HSCT rescued with donor lymphocytes infusions in a patient with X-linked chronic granulomatous disease
por: Scheiermann, Julia, et al.
Publicado: (2023)

How do we choose the best donor for T-cell-replete, HLA-haploidentical transplantation?
por: Chang, Ying-Jun, et al.
Publicado: (2016)

Alternative donor transplantation for acute myeloid leukemia in patients aged ≥50 years: young HLA-matched unrelated or haploidentical donor?
por: Perales, Miguel-Angel, et al.
Publicado: (2020)

1763. The Use of Haploidentical Donors Compared with HLA-Matched Unrelated Donors is Associated with Increased Risk of BK Viruria and Hemorrhagic Cystitis
por: Morgan. Scott, Mary, et al.
Publicado: (2019)

Donor Specific Anti-HLA Antibody and Risk of Graft Failure in Haploidentical Stem Cell Transplantation
por: Kongtim, Piyanuch, et al.
Publicado: (2016)

Haploidentical Stem Cell Transplantation: A Gateway to Infrequent Availability of HLA-Matched Related Donors
por: Aslam, Hafiz Muhammad, et al.
Publicado: (2018)

Preventive infusion of donor-derived CAR-T cells after haploidentical transplantation: Two cases report
por: Zhang, Cheng, et al.
Publicado: (2019)

Haploidentical vs matched sibling donor transplant for paroxysmal nocturnal haemoglobinuria: A multicenter study
por: Liu, Limin, et al.
Publicado: (2022)

A Prospective Trial Comparing Haploidentical Donor Transplantation With Cord Blood Versus HLA-Matched Sibling Donor Transplantation for Hematologic Malignancy Patients
por: Lu, Wenyi, et al.
Publicado: (2022)

Optimizing autologous hematopoietic stem cell transplantation for acute leukemia
por: Pang, Aiming, et al.
Publicado: (2021)

Haploidentical vs matched unrelated donors for patients with ALL: donor age matters more than donor type
por: Mehta, Rohtesh S., et al.
Publicado: (2023)

Post-transplantation Cyclophosphamide: From HLA-Haploidentical to Matched-Related and Matched-Unrelated Donor Blood and Marrow Transplantation
por: Williams, Louis, et al.
Publicado: (2020)

Donor lymphocyte infusion for prevention of relapse after unmanipulated haploidentical PBSCT for very high-risk hematologic malignancies
por: Gao, Xiao-Ning, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_s6d8o7f0cnbq9k3i402vkge5v5